scPharmaceuticals (SCPH) Expected to Announce Quarterly Earnings on Wednesday

scPharmaceuticals (NASDAQ:SCPH) is projected to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect scPharmaceuticals to post earnings of ($0.39) per share and revenue of $12.08 million for the quarter.

scPharmaceuticals Price Performance

Shares of scPharmaceuticals stock opened at $2.89 on Tuesday. scPharmaceuticals has a 1-year low of $2.75 and a 1-year high of $6.20. The firm’s 50-day moving average price is $3.37 and its two-hundred day moving average price is $3.91. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $144.62 million, a price-to-earnings ratio of -1.52 and a beta of 0.40.

Analyst Upgrades and Downgrades

SCPH has been the topic of a number of research reports. Craig Hallum cut their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Monday, March 3rd.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.